immune-话题@MedSci

#immune#

10篇内容 | 749人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1519417, encodeId=4f6f151941ee9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据, objectType=article, longId=220575, objectId=ad652205e545, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad652205e545, replyNumber=0, likeNumber=21, createdTime=2021-11-20, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad652205e545, moduleTitle=Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad652205e545)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519416, encodeId=5eaf1519416a7, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=Immune-Onc靶向LILRB2（ILT4）全新抑制性抗体IO-108获FDA批准将在晚期实体瘤中开展人体临床试验, objectType=article, longId=215703, objectId=edd2215e036a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edd2215e036a, replyNumber=0, likeNumber=31, createdTime=2021-08-15, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edd2215e036a, moduleTitle=Immune-Onc靶向LILRB2（ILT4）全新抑制性抗体IO-108获FDA批准将在晚期实体瘤中开展人体临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edd2215e036a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519415, encodeId=400c15194159e, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=Boston Immune与百济神州签订**选择权和许可协议，以开发新型TNFR2抗体, objectType=article, longId=207250, objectId=061e20e25043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=061e20e25043, replyNumber=0, likeNumber=41, createdTime=2021-02-20, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=061e20e25043, moduleTitle=Boston Immune与百济神州签订**选择权和许可协议，以开发新型TNFR2抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=061e20e25043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519414, encodeId=8de41519414ba, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, objectType=article, longId=191868, objectId=b01e191868d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01e191868d2, replyNumber=0, likeNumber=35, createdTime=2020-04-11, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01e191868d2, moduleTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01e191868d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519413, encodeId=f3171519413fa, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=Aimmune的Palforzia成为美国批准的**种花生过敏治疗药物, objectType=article, longId=187153, objectId=ed5018e153aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed5018e153aa, replyNumber=0, likeNumber=35, createdTime=2020-02-03, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed5018e153aa, moduleTitle=Aimmune的Palforzia成为美国批准的**种花生过敏治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed5018e153aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519412, encodeId=7f4b151941242, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=FDA支持Aimmune的花生过敏疗法Palforzia, objectType=article, longId=179447, objectId=8a871e9447d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a871e9447d1, replyNumber=0, likeNumber=47, createdTime=2019-09-16, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a871e9447d1, moduleTitle=FDA支持Aimmune的花生过敏疗法Palforzia, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a871e9447d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=Adaptimmune和Noile-Immune宣布合作，开发增强型SPEAR T细胞肿瘤免疫疗法, objectType=article, longId=178294, objectId=d7c31e8294c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7c31e8294c4, replyNumber=0, likeNumber=41, createdTime=2019-08-30, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7c31e8294c4, moduleTitle=Adaptimmune和Noile-Immune宣布合作，开发增强型SPEAR T细胞肿瘤免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7c31e8294c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519410, encodeId=1de815194101f, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=Aimmune制药在2018 EAACI上公布AR101治疗花生过敏的全新临床数据, objectType=article, longId=139444, objectId=fbd613944467, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbd613944467, replyNumber=0, likeNumber=44, createdTime=2018-05-31, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbd613944467, moduleTitle=Aimmune制药在2018 EAACI上公布AR101治疗花生过敏的全新临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbd613944467)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519409, encodeId=0090151940998, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=Neuroimmune Pharmacology：肉桂有助于改善民众记忆力, objectType=article, longId=73100, objectId=2d7ee310039, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d7ee310039, replyNumber=0, likeNumber=0, createdTime=2016-07-20, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d7ee310039, moduleTitle=Neuroimmune Pharmacology：肉桂有助于改善民众记忆力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d7ee310039)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519408, encodeId=3f681519408a8, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, objectTitle=MedImmune携手Juno！CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章？！, objectType=article, longId=49896, objectId=41ff498968d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ff498968d, replyNumber=0, likeNumber=26, createdTime=2015-04-29, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ff498968d, moduleTitle=MedImmune携手Juno！CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章？！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ff498968d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

immune

2020-05-29

quxin068 (审核中...)

前往app查看评论内容

#immune#

Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据

2021-11-20

quxin068 (审核中...)

前往app查看评论内容

#immune#

Immune-Onc靶向LILRB2（ILT4）全新抑制性抗体IO-108获FDA批准将在晚期实体瘤中开展人体临床试验

2021-08-15

quxin068 (审核中...)

前往app查看评论内容

#immune#

Boston Immune与百济神州签订**选择权和许可协议，以开发新型TNFR2抗体

2021-02-20

quxin068 (审核中...)

前往app查看评论内容

#immune#

OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准

2020-04-11

quxin068 (审核中...)

前往app查看评论内容

#immune#

Aimmune的Palforzia成为美国批准的**种花生过敏治疗药物

2020-02-03

quxin068 (审核中...)

前往app查看评论内容

#immune#

FDA支持Aimmune的花生过敏疗法Palforzia

2019-09-16

quxin068 (审核中...)

前往app查看评论内容

#immune#

Adaptimmune和Noile-Immune宣布合作，开发增强型SPEAR T细胞肿瘤免疫疗法

2019-08-30

quxin068 (审核中...)

前往app查看评论内容

#immune#

Aimmune制药在2018 EAACI上公布AR101治疗花生过敏的全新临床数据

2018-05-31

quxin068 (审核中...)

前往app查看评论内容

#immune#

Neuroimmune Pharmacology：肉桂有助于改善民众记忆力

2016-07-20

quxin068 (审核中...)

前往app查看评论内容

#immune#

MedImmune携手Juno！CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章？！

2015-04-29

科室
- - 订阅+
  - 更多科室
工具
服务